Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.4 USD | +3.30% | +8.14% | -19.73% |
04-23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
04-22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 28.89 and 26.13 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.73% | 72.39B | B+ | ||
-11.01% | 6.54B | B- | ||
+15.88% | 3.43B | B- | ||
-0.68% | 1.4B | - | ||
-17.27% | 1.34B | B | ||
-2.73% | 1.26B | - | ||
-28.16% | 1.2B | C- | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - | ||
-24.06% | 805M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.